150 related articles for article (PubMed ID: 31355511)
1. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
[TBL] [Abstract][Full Text] [Related]
2. BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.
Liu G; Cuffe S; Liang S; Azad AK; Cheng L; Brhane Y; Qiu X; Cescon DW; Bruce J; Chen Z; Cheng D; Patel D; Tse BC; Laurie SA; Goss G; Leighl NB; Hung R; Bradbury PA; Seymour L; Shepherd FA; Tsao MS; Chen BE; Xu W; Reisman DN
Clin Cancer Res; 2017 May; 23(10):2460-2470. PubMed ID: 27827316
[No Abstract] [Full Text] [Related]
3. Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.
Korpanty GJ; Eng L; Qiu X; Faluyi OO; Renouf DJ; Cheng D; Patel D; Chen Z; Tse BC; Knox JJ; Dodbiba L; Teichman J; Azad AK; Wong R; Darling G; Reisman D; Cuffe S; Liu G; Xu W
Oncotarget; 2017 Apr; 8(17):28093-28100. PubMed ID: 28427211
[TBL] [Abstract][Full Text] [Related]
4. Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.
Wong KM; Qiu X; Cheng D; Azad AK; Habbous S; Palepu P; Mirshams M; Patel D; Chen Z; Roberts H; Knox J; Marquez S; Wong R; Darling G; Waldron J; Goldstein D; Leighl N; Shepherd FA; Tsao M; Der S; Reisman D; Liu G
Cancer Med; 2014 Apr; 3(2):426-33. PubMed ID: 24519853
[TBL] [Abstract][Full Text] [Related]
5. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
[TBL] [Abstract][Full Text] [Related]
6. Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma.
Pasic I; Wong KM; Lee JJ; Espin-Garcia O; Brhane Y; Cheng D; Chen Z; Patel D; Brown C; Bucur R; Reisman D; Knox JJ; Xu W; Hung RJ; Liu G; Cleary SP
Mol Carcinog; 2018 Jan; 57(1):106-113. PubMed ID: 28892201
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
8. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
9. Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.
Liu G; Gramling S; Munoz D; Cheng D; Azad AK; Mirshams M; Chen Z; Xu W; Roberts H; Shepherd FA; Tsao MS; Reisman D
Oncogene; 2011 Jul; 30(29):3295-304. PubMed ID: 21478907
[TBL] [Abstract][Full Text] [Related]
10. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
11. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
[TBL] [Abstract][Full Text] [Related]
12. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
[TBL] [Abstract][Full Text] [Related]
13. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
[TBL] [Abstract][Full Text] [Related]
15. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
16. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
[TBL] [Abstract][Full Text] [Related]
18. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
19. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
20. Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer.
Yu Y; Cheng D; Parfrey P; Liu G; Savas S
PLoS One; 2018; 13(6):e0198873. PubMed ID: 29894502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]